Newamsterdam Pharma Stock Today
| NAMSW Stock | 9.69 0.16 1.68% |
Performance9 of 100
| Odds Of DistressOver 70
|
NewAmsterdam Pharma is selling for under 9.69 as of the 28th of November 2024; that is 1.68 percent up since the beginning of the trading day. The stock's lowest day price was 9.5. NewAmsterdam Pharma has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for NewAmsterdam Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of November 2022 | Category Healthcare | Classification Health Care |
NewAmsterdam Pharma is entity of United States. It is traded as Stock on NASDAQ exchange. More on NewAmsterdam Pharma
Moving together with NewAmsterdam Stock
| 0.78 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against NewAmsterdam Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NewAmsterdam Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | FACC Facp | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NewAmsterdam Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NewAmsterdam Pharma's financial leverage. It provides some insight into what part of NewAmsterdam Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NewAmsterdam Pharma (NAMSW) is traded on NASDAQ Exchange in USA. It is located in Gooimeer 2-35, Naarden, Netherlands, 1411 DC and employs 62 people. NewAmsterdam Pharma is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
NewAmsterdam Pharma generates negative cash flow from operations
Check NewAmsterdam Pharma Probability Of Bankruptcy
NewAmsterdam Pharma Historical Income Statement
NewAmsterdam Stock Against Markets
NewAmsterdam Pharma Corporate Management
| Louise Kooij | Treasurer, CFO | Profile | |
| Jim Jacobson | Chief Secretary | Profile | |
| Annie Neild | VP Affairs | Profile | |
| FESC MD | Chief Founder | Profile | |
| Marc MD | Chief Officer | Profile | |
| MSc MBA | Chief Officer | Profile | |
| Lina Gugucheva | Chief Officer | Profile |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.